FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 10:09:46 01/07/2024 BST | ||
| 48.99 EUR / 49.03 EUR | +0.18% |
|
| Current month | +16.87% | ||
| 1 month | +18.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 49.01 | +0.18% |
| 28/06/24 | 48.92 | -0.87% |
| 27/06/24 | 49.35 | -0.52% |
| 26/06/24 | 49.61 | +1.18% |
| 25/06/24 | 49.03 | +3.26% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 08:44 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD3RFM |
| ISIN | DE000MD3RFM2 |
| Date issued | 21/04/2022 |
| Strike | 503.1 kr |
| Maturity | Unlimited |
| Parity | 1.36 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.19 € |
|---|---|
| Lowest since issue | 8.23 € |
| Spread | 0.04 € |
| Spread % | 0.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
